Terms: = Thyroid cancer AND DEK, D6S231E, 7913, ENSG00000124795, P35659
4 results:
1. Relationship between thyroid-stimulating hormone levels and risk of depression among the general population with normal free T4 levels.
Kim EY; Kim SH; Rhee SJ; Huh I; Ha K; Kim J; Chang JS; Yoon DH; Park T; Ahn YM
Psychoneuroendocrinology; 2015 Aug; 58():114-9. PubMed ID: 25973566
[TBL] [Abstract] [Full Text] [Related]
2. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
Thyroid; 2012 Mar; 22(3):310-7. PubMed ID: 22313411
[TBL] [Abstract] [Full Text] [Related]
3. thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
Kitajima K; Takahashi S; Maeda T; Yoshikawa T; Ohno Y; Fujii M; Miyake H; Fujisawa M; Sugimura K
Eur J Radiol; 2012 Sep; 81(9):2060-5. PubMed ID: 21724350
[TBL] [Abstract] [Full Text] [Related]
4. Follicular variant of papillary thyroid carcinoma: clinical-pathological characterization and long-term follow-up.
Hagag P; Hod N; Kummer E; Cohenpour M; Horne T; Weiss M
Cancer J; 2006; 12(4):275-82. PubMed ID: 16925971
[TBL] [Abstract] [Full Text] [Related]
